News
SLDB
7.28
-0.14%
-0.01
Solid Biosciences: A Funded Challenge To Duchenne Gene Therapy's Limitations
Seeking Alpha · 3d ago
Weekly Report: what happened at SLDB last week (0914-0918)?
Weekly Report · 09/21 09:06
RBC Capital Initiates Coverage of Solid Biosciences at Outperform
NASDAQ · 09/16 21:57
Solid Biosciences wins new Outperform at RBC on DMD opportunity
Seeking Alpha · 09/16 16:15
Cantor Fitzgerald Sticks to Its Buy Rating for Solid Biosciences (SLDB)
TipRanks · 09/16 12:55
Solid Biosciences: Buy Rating Reiterated With Unchanged $20 Price Target on Clinical and Regulatory Upside Potential
TipRanks · 09/16 12:55
Solid Biosciences Price Target Announced at $18.00/Share by RBC Capital
Dow Jones · 09/16 12:19
This Brinker Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday
Benzinga · 09/16 12:14
RBC Capital Initiates Coverage On Solid Biosciences with Outperform Rating, Announces Price Target of $18
Benzinga · 09/16 12:09
Solid Biosciences initiated with an Outperform at RBC Capital
TipRanks · 09/16 10:10
Solid Biosciences Price Target Maintained With a $25.00/Share by HC Wainwright & Co.
Dow Jones · 09/14 11:50
HC Wainwright & Co. Reiterates Buy on Solid Biosciences, Maintains $25 Price Target
Benzinga · 09/14 11:40
Analysts’ Top Healthcare Picks: Pharming Group (PHAR), Solid Biosciences (SLDB)
TipRanks · 09/14 10:40
Weekly Report: what happened at SLDB last week (0907-0911)?
Weekly Report · 09/14 09:07
Solid Biosciences (SLDB) Gets a Buy from Citi
TipRanks · 09/11 10:16
Solid Biosciences management to meet with Cantor
TipRanks · 09/09 21:20
Weekly Report: what happened at SLDB last week (0831-0904)?
Weekly Report · 09/07 09:06
Solid Biosciences Insiders Sell US$823k Of Stock, Possibly Signalling Caution
Simply Wall St · 09/03 10:12
Weekly Report: what happened at SLDB last week (0824-0828)?
Weekly Report · 08/31 09:07
Nvidia To Rally Around 146%? Here Are 10 Top Analyst Forecasts For Thursday
Benzinga · 08/27 13:19
More
Webull provides a variety of real-time SLDB stock news. You can receive the latest news about Solid Bioscience through multiple platforms. This information may help you make smarter investment decisions.
About SLDB
Solid Biosciences Inc. is a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases. The Company is focused on advancing a portfolio of gene therapy candidates including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy and additional assets for the treatment of genetic cardiac and neuromuscular disease. It also has two cardiac pipeline gene transfer programs, SGT-401 for BAG3-mediated DCM, which is in early preclinical development, and SGT-701 for RBM20 DCM, which is in the discovery stage. In addition to its gene transfer candidates, the Company has development programs focusing on platform technologies, including capsid libraries and dual gene expression, a technology that allows it to package multiple transgenes into one capsid.